Trial Profile

A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; Fianlimab (Primary) ; Ipilimumab (Primary) ; Nivolumab
Indications Renal cell carcinoma
Focus Therapeutic Use

Most Recent Events

03 Apr 2026 Planned initiation date (estimated date of first patient enrollment) changed from 1 Mar 2026 to 1 Apr 2026.
03 Apr 2026 Planned End Date changed from 1 Nov 2030 to 30 Nov 2030.
03 Apr 2026 Planned primary completion date changed from 1 Nov 2029 to 30 Nov 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com